Clinicopathological Characteristics of HER2-Positive Breast Cancer Patients with BRCA1/2 Pathogenic Variants and Their Response to Neoadjuvant Targeted Therapy

Clinicopathological Characteristics of HER2-Positive Breast Cancer Patients with BRCA1/2 Pathogenic Variants and Their Response to Neoadjuvant Targeted Therapy

ObjectiveTo analyze the proportion and clinicopathological characteristics of HER2-positive breast cancer patients with BRCA1/2 pathogenic variants, and their response to neoadjuvant anti-HER2 targeted therapy. MethodsThe clinicopathological data of 531 breast cancer patients with germline BRCA1/2 p...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xingyu LIAO, Huimin LIU, Jie SUN, Li HU, Juan ZHANG, Lu YAO, Ye XU, Yuntao XIE
Format:	Article
Language:	zho
Published:	Magazine House of Cancer Research on Prevention and Treatment 2025-06-01
Series:	Zhongliu Fangzhi Yanjiu
Subjects:	brca1/2 pathogenic variant her2-positive breast cancer clinicopathological characteristic neoadjuvant therapy
Online Access:	http://www.zlfzyj.com/cn/article/doi/10.3971/j.issn.1000-8578.2025.25.0101
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Oncotype DX Recurrence Score and Germline BRCA Variants in Patients with HR-Positive/HER2-Negative Early Breast Cancer: A Retrospective Observational Study
by: Stefania Morganti, et al.
Published: (2025-04-01)

Molecular analysis of BRCA1 and BRCA2 genes in La Rioja (Spain): five new variants
by: Raquel Salazar Saez, et al.
Published: (2024-10-01)

Comparison of outcomes of neoadjuvant chemotherapy in BRCA1- versus BRCA2-associated breast and ovarian cancers
by: Anna Sokolenko, et al.
Published: (2025-06-01)

Study on clinicopathological features and prognosis of HER2 low expression breast cancer
by: RUAN Miao, DA Qian, XU Haimin, DONG Lei, FEI Xiaochun
Published: (2024-10-01)

Unveiling HER2 immunoexpression in canine hepatoid gland neoplasms: clinicopathological and morphological associations
by: Hassadin Boonsriroj, et al.
Published: (2025-12-01)

Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study
by: Karen Van Baelen, et al.
Published: (2025-06-01)

Part I: consensus statements and expert recommendations for HER2-negative early breast cancer in the Asia-Pacific region: diagnosis and risk assessment
by: Soo Chin Lee, et al.
Published: (2025-06-01)

Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical management
by: Yeon Hee Park, et al.
Published: (2025-06-01)

Genetic trends and common BRCA1/2 pathogenic sequence variants in black African and Indian breast cancer patients presenting at Inkosi Albert Luthuli Central Hospital, KwaZulu-Natal, South Africa
by: M Makhetha, et al.
Published: (2024-05-01)

Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade
by: V. F. Semiglazov, et al.
Published: (2024-11-01)

Prevalence of germline BRCA1/2 pathogenic variants in unselected Korean patients with HER2-negative metastatic breast cancer: a nationwide prospective study (KCSG BR19-10)Research in context
by: Hee Kyung Ahn, et al.
Published: (2025-07-01)

Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis
by: Francisco Cezar Aquino de Moraes, et al.
Published: (2025-03-01)

Real‐World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1‐2 Pathogenic Variants
by: Michele Milella, et al.
Published: (2025-02-01)

Generating a database by calculating the pathogenic variants and allele frequencies detected in hereditary cancers using genomic data: A nation study
by: Manal Salah Babiker Ali, et al.
Published: (2025-09-01)

Regional Differences in the Frequency of BRCA1 and BRCA2 Variants in Northeastern Japan: A Cohort Study
by: Hidekazu Shirota, et al.
Published: (2025-04-01)

Clinicopathological features of Lynch syndrome pedigrees with MSH2 c.351G>A gene variant
by: Shuai Zhang, et al.
Published: (2025-01-01)

Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy
by: Charles E. Geyer, Jr., et al.
Published: (2025-06-01)

De-escalated neoadjuvant nab-paclitaxel combined with pyrotinib and trastuzumab in intrinsic HER2-enriched breast cancer (NJMU-BC01): a multicenter, single-arm, phase 2 trialResearch in context
by: Hong Pan, et al.
Published: (2025-08-01)

Distribution of age at natural menopause, age at menarche, menstrual cycle length, height and BMI in BRCA1 and BRCA2 pathogenic variant carriers and non-carriers: results from EMBRACE
by: Nasim Mavaddat, et al.
Published: (2025-05-01)

Clinicopathological characteristics and long-term prognosis of triple-negative breast cancer patients with HER2-Low expression: a retrospective propensity score-matched cohort study
by: Xin Liu, et al.
Published: (2024-12-01)

Clinical significance of HER2 overexpression in biliary tract carcinoma ——a meta analysis
by: Haonan Xu, et al.
Published: (2025-05-01)

Prophylactic adnexectomy in BRCA1 and BRCA2 gene mutation carriers (а review of literature)
by: T. A. Shendrikova, et al.
Published: (2014-07-01)

Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy
by: Yingbo Shao, et al.
Published: (2025-03-01)

Association between single nucleotide polymorphisms of DNA repair genes (BRCA1, BRCA2, and PALB2) and breast cancer incidence in a subset of Iranian population
by: Sepideh Jahangiri, et al.
Published: (2025-03-01)

Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial
by: Mark Hensley, et al.
Published: (2025-07-01)

Neoadjuvant compared to adjuvant chemotherapy combined with trastuzumab in patients with HER2-positive breast cancer: a register-based cohort study
by: S. Hosseini-Mellner, et al.
Published: (2024-12-01)

Analysis of methylation features associated with neoadjuvant efficacy in HER2-positive breast cancer
by: Zibai Guo, et al.
Published: (2025-08-01)

Breast cancer risk associated with BRCA1 and BRCA2 pathogenic variants in the Eastern Chinese population
by: Sanjian Yu, et al.
Published: (2025-03-01)

Study of the Carrier State for Five BRCA1/BRCA2 Deleterious Mutations in Bulgarian Women with Breast Cancer
by: Katia Kovacheva, et al.
Published: (2013-12-01)

Druggable Molecular Networks in <i>BRCA1/BRCA2</i>-Mutated Breast Cancer
by: Francesca Pia Carbone, et al.
Published: (2025-03-01)

Role of BRCA 1 и BRCA 2 gene mutations in the occurrence of male breast cancer
by: A. V. Bykova, et al.
Published: (2014-07-01)

A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)Key Points:
by: Maeve A. Hennessy, et al.
Published: (2025-06-01)

A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2‐ breast cancer‐FINEST study
by: Li Chen, et al.
Published: (2025-04-01)

Response and prognosis to neoadjuvant chemotherapy in women early breast cancer of HER2-low status
by: Yongtao Li, et al.
Published: (2025-06-01)

BRCA1, BRCA2 mutations — future of predictive oncology: a review of literature
by: V. N. Dmitriev, et al.
Published: (2014-07-01)

Characterization and functional analysis of BRCA1 and BRCA2 variants in a cohort of 100 unselected patients undergoing germline screening
by: Qianqian Shi, et al.
Published: (2025-09-01)

Pathologic Response and Survival Outcomes on HER2-Low vs. HER2-Zero in Breast Cancer Receiving Neoadjuvant Chemotherapy
by: Rumeysa Colak, et al.
Published: (2025-06-01)

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity
by: Eliana MC Tacconi, et al.
Published: (2017-07-01)

Concordance Between ER, PR, HER2 neu Receptors Before and After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
by: Taha Heba F., et al.
Published: (2021-05-01)

Impact of germline BRCA1/2 mutations on response to neoadjuvant systemic therapy and prognosis in breast cancer: a propensity score matched cohort study
by: Hyunyou Kim, et al.
Published: (2025-05-01)